Dr. James Phillips MB ChB MBA
-Jim is a registered Physician who also holds an MBA from Cass Business School in London. Previously the CEO of Midatech Pharma for 5 years, Jim (James) Phillips holds 2 Non-executive directorships in Europe - PreciHealth SA & Herantis Pharma OY. He was President of EUSA Pharma Europe in its key growth phase prior to its sales in 2012 to Jazz Pharma, CEO & founder in Talisker Pharma (sold in 2006 to EUSA Pharma) and also SVP Corporate Development at EUSA; he founded Talisker Pharma in 2004 which was acquired by EUSA in 2006. Jim was also Chairman of Prosonix Ltd between 2007-12 prior to its successful sale to Circassia. Jim previously worked for Johnson & Johnson and Novartis as a senior executive.
Volker Wedershoven holds a degree in Business Administration from the LMU Munich. He started his career as the assistant to the managing director of a company in the machinery business. The company specialized in developing, constructing and servicing dedicated machines for the pharmaceutical industry.
Volker Wedershoven acquired his first shares in the company in 1992 and was a major shareholder by the time of selling the company. In 1992 he was announced Managing Director. Until 2010 the company went through a successful growth process from 35 employees to 480 employees. He established two daughter companies in the USA and additional sales points in Europe and Asia. The two shareholders in the company accepted an offer to sell in 2010.
After selling the company, he worked as a consultant and Business Angel in various projects in different industries. Volker Wedershoven now serves as Chief Financial Officer (CFO) at ImevaX.
Dr. Uwe Michaelis
Dr. Uwe Michaelis obtained a Ph.D. from the Institute of Genetics and Microbiology of the Ludwigs-Maximilians Universität (LMU) in Munich. From 1991 to 1998, he held various positions at Boehringer Mannheim GmbH/ROCHE in the area of research and development of biotechnology-based drugs.
In 1998, Dr. Uwe Michaelis co-founded Munich Biotech AG, where he served as CSO. His extensive experience in all phases of company startup was the prerequisites for growing Munich Biotech AG to some 60 employees and taking the development of drug candidates to clinical phase I trials.
After the takeover of Munich Biotech AG by MediGene AG in 2004, Dr. Uwe Michaelis initially served as Vice President Research before becoming VP Early-Stage Drug Development. While he was the project leader of “Strategic Investments”, the oncological herpes simplex virus (HSV) platform was spun out into the US company Catherex.
In 2012, he founded his business consultancy, MICHAELIS BIOSCIENCE. Dr. Uwe Michaelis currently advises ImevaX on early-stage drug development and manufacturing issues. As COO he is leading all development activities.